BUZZ-Lexeo rises as it announces leadership changes
I'm PortAI, I can summarize articles.
Shares of drug developer Lexeo Therapeuticsrise 2% to $7.63 premarketCo says it named cardiologist Dr. Narinder Bhalla as chief medical officerCo says its research head Dr. Eric Adler will become CEO of Myoventive, which focuses on RNA-based treatments for inherited heart conditionsCTO José Manuel Otero moves to the chief operating officer’s role; co also hires two VPs to lead early- and late-stage cardiology programs - LXEOShares up ~51% in 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments